Immune Response Data from Phase II Melanoma Trial and Preliminary Combination Study Findings Will Be Presented
SAN DIEGO – July 15, 2013 — OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, will host a satellite symposium at the 8th World Congress of Melanoma in Hamburg, Germany on Thursday, July 18 at 3:00 – 4:00PM CEST.
The symposium, titled “Advances in Gene Electrotransfer: An Emerging Intralesional Therapy for Metastatic Melanoma”, will be chaired by Axel Hauschild, M.D., Ph.D., professor and head of the Interdisciplinary Skin Cancer, Center at the Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany, and a member of OncoSec’s Melanoma Advisory Board.
The symposium agenda is as follows:
About the World Congress of Melanoma/European Association of Dermato-Oncology (EADO) Congress
The World Congress of Melanoma attracts the international melanoma community of basic researchers and clinicians. The 8th World Congress of Melanoma will be organized in conjunction with the 9th Congress of the European Association of Dermato-Oncology (EADO), the World Meeting of Melanoma Centers, and the Post-Chicago Melanoma Meeting 2013. The EADO Congress includes non-melanoma skin cancer and cutaneous lymphomas as topics. This congress will cover the entire field of melanoma and other cutaneous malignancies. Epidemiology, prevention and early detection of skin cancer are important fields in order to reverse the current trend of increasing incidences. New diagnostic devices and optical approaches have improved the diagnostic sensitivity and specificity and are discussed extensively. Patient management issues including psychosocial aspects and the follow-up for high risk patients are aspects of the program, too. Furthermore, basic science results for melanoma and other skin cancers will be presented in plenary lectures and during symposia. Other cutaneous malignancies are the main topic during the EADO sessions. For more information, please visit www.worldmelanoma2013.com.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical’s core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.